USV slashes price of diabetes drug Jalra DP by 20 percent

Published On 2022-10-10 08:32 GMT   |   Update On 2024-08-20 06:57 GMT
Advertisement

In a move to make diabetes therapy more accessible to patients, Indian pharma major USV has brought down the price of its product Jalra-DP, the commonly used antidiabetic drug. 

JALRA DP is a combination of Vildaglitpin 100mg SR (sustained release) & Dapagliflozin 10mg which was earlier costing Rs 25 per tablet or Rs 250 per strip will now be available at price of Rs 19.9 per tablet.

Advertisement
Jalra-DP is indicated for the treatment of type 2 diabetes which works by improving both insulin resistance and beta cell function. Jalra-DP is usually prescribed when metformin alone or Sulfonylurea + metformin is ineffective in controlling Type-2 diabetes mellitus.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by USV Pvt. Ltd.

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News